Table 2.

Therapeutic effects of chemokine receptor inhibitors in preclinical studies.

Target	Inhibitor	Tumor Type	Outcome	Reference
CCR2	CCX872 + anti-PD-1	Murine glioma model	Decrease MDSC Enhance anti-PD-1 effect Antitumor effect	[200]
	RS504393 + anti-PD-1	Murine breast cancer and melanoma models	Decrease TAM Antitumor effect	[201]
CCR4	Mogamulizumab + Piroxicam	Canine bladder cancer model	Decrease Treg cell Antitumor effect	[202]
	CCR4-351 + anti-CTLA-4 or anti-4-1BB	Murine pancreatic cancer model	Decrease Treg cell Antitumor effect	[63]
CCR5	mCCR5–Ig fusion antibody	Murine melanoma model	Decrease MDSC Antitumor effect	[203]
CCR8	JTX-1811	Multiple murine cancer models	Deplete tumor Treg cell but not normal tissue Treg cell Antitumor effect	[204]
	SRF114	In vitro study	Deplete Treg cell	[205]
	HBM1022 alone or + Pembrolizumab	Multiple murine cancer models	Deplete Treg cell Antitumor effect	[206]
	FPA157	Murine colon cancer models	Deplete Treg cell Antitumor effect	[207]
	25B3	Multiple murine cancer models	Deplete Treg cell Antitumor effect	[208]
CXCR2	SB225002 + Cisplatin	Murine lung cancer model	Decrease neutrophil Enhance anti-tumor CD8+ T cell activation Antitumor effect	[196]

Mogamulizumab (anti-CCR4); Pembrolizumab (anti-PD-1).